“Fail fast, fail early” is a mantra often recited in today’s pharmaceutical and biotechnology industry. Escalating drug discovery and development costs1 plus the need to promptly accelerate potential new therapies to market within evermore challenging timelines means that quick and iterative selection of the best possible drug candidates becomes a key ratedetermining activity. The cost of late stage failures can be astronomical so rapid elimination of the least promising drug candidates throughout the preclinical drug discovery phase is an essential and ongoing requirement.

To select the most productive path through preclinical drug discovery the drug discovery team therefore needs help to limit the number of medicinal chemistry blind-alleys explored during prioritisation and refinement of drug candidates on the path to a more optimal balance of on-target activity, physicochemical properties and pharmacokineticpharmacodynamic

profile.

Publications from Evotec